PFO - Patent Foramen Ovale
14
5
8
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
14.3%
2 terminated out of 14 trials
33.3%
-53.2% vs benchmark
7%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (14)
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
Abbott Structural Heart Device Registry
Trevisio Post-Approval Study
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device
A Comparison of Biodegradable and Metal Occluders in Patients With PFO and Migraine
Japan Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder
WSO BEAT STROKE Initiative
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine
GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
Amplatzer PFO Occluder Post-marketing Surveillance Study
The PROOF Trial - Prospective, Open-label, Multicenter, Non-randomized Investigation on Percutaneous Patent Foramen Ovale (PFO) Closure Using the Occlutech PFO Occluder to Prevent Recurrence of Stroke in Patients With Cryptogenic Stroke and High Risk PFO
Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)
COMPETE Cohort Study